Document:

CONSULTING SERVICES AGREEMENT

This Consulting Agreement ("Agreement"), dated February 7, 2000,
is made by and between Edward James Wexler, an individual
("Consultant"), whose address is P.O. Box 1029, Debary, Florida
32713, and eConnect, a Nevada corporation ("Client"), having its
principal place of business at 2500 Via Cabrillo Marina, Suite
112, San Pedro, California 90731.

WHEREAS, Consultant has knowledge and expertise in the area of
operating an internet company known as PowerClick, Inc., a Nevada
corporation, and including development of sites on the World Wide
Web portions of the Internet and information about publicly
traded companies, the use of the media known as the Internet, and
the evaluation of company operations, as well as the coordination
of and compatibility between several aspects and/or division or
same or related web sites and the underlying companies involved;

WHEREAS, Consultant desires to be engaged by Client to provide
information, evaluation and consulting services to the Client in
his area of knowledge and expertise on the terms and subject to
the conditions set forth herein;

WHEREAS, Client is a publicly held corporation with its common
stock shares trading on the Over the Counter Bulletin Board under
the ticker symbol "ECNC," and desires to further develop its
business and increase it's common stock share's value adding
additional lines of business of the Client, including the
acquisition of PowerClick, Inc. by the Client, and properly
managing existing e-commerce websites; and

WHEREAS, Client desires to engage Consultant to provide
information, evaluation and consulting services to the Client in
his area of knowledge and expertise on the terms and subject to
the conditions set forth herein.

NOW, THEREFORE, in consideration for those services Consultant
provides to Client, the parties agree as follows:

1.  Services of Consultant.

Consultant agrees to perform for the Client all services and
consulting related to managing the operation of PowerClick, Inc.
after its acquisition by Client, in managing other websites owned
and operated by the Client, including development of sites on the
World Wide Web portions of the Internet, the use of the Internet,
and the evaluation of company operations, as well as the
coordination of and compatibility between several aspects and/or
division or same or related web sites.  Consulting services
include, but are not limited to, providing information,
evaluation, and analysis with regard to the operation of such
properties.

2.  Consideration.

Client agrees to pay Consultant, as his fee and as consideration
for services provided, Five Hundred Thousand (500,000) shares of
S-8 free trading common stock in Client. Shares are due and
payable immediately upon the effectiveness of the Form S-8
Registration Statement with the U.S. Securities and Exchange
Commission and with any appropriate states securities
administrator.

3.  Confidentiality.

Each party agrees that during the course of this Agreement,
information that is confidential or of a proprietary nature may
be disclosed to the other party, including, but not limited to,
product and business plans, software, technical processes and
formulas, source codes, product designs, sales, costs and other
unpublished financial information, advertising revenues, usage
rates, advertising relationships, projections, and marketing data
("Confidential Information"). Confidential Information shall not
include information that the receiving party can demonstrate (a)
is, as of the time of its disclosure, or thereafter becomes part
of the public domain through a source other than the receiving
party, (b) was known to the receiving party as of the time of its
disclosure, (c) is independently developed by the receiving party
or (d) is subsequently learned from a third party not under a
confidentiality obligation to the providing party.

4.  Late Payment.

Client shall pay to Consultant all fees within fifteen (15) days
of the due date. Failure of Client to finally pay any fees within
fifteen (15) days after the applicable due date shall be deemed a
material breach of this Agreement, justifying suspension of the
performance of the "Services" provided by Consultant, will be
sufficient cause for immediate termination of this Agreement by
Consultant. Any such suspension will in no way relieve Client
from payment of fees, and, in the event of collection
enforcement, Client shall be liable for any costs associated with
such collection, including, but not limited to, legal costs,
attorneys' fees, courts costs, and collection agency fees.

5.  Indemnification.

(a)  Client.

Client agrees to indemnify, defend, and shall hold harmless
Consultant and /or his agents, and to defend any action brought
against said parties with respect to any claim, demand, cause of
action, debt or liability, including reasonable attorneys' fees
to the extent that such action is based upon a claim that: (i) is
true, (ii) would constitute a breach of any of Client's
representations, warranties, or agreements hereunder, or (iii)
arises out of the negligence or willful misconduct of Client, or
any Client Content to be provided by Client and does not violate
any rights of third parties, including, without limitation,
rights of publicity, privacy, patents, copyrights, trademarks,
trade secrets, and/or licenses.

(b)  Consultant.

Consultant agrees to indemnify, defend, and shall hold harmless
Client, its directors, employees and agents, and defend any
action brought against same with respect to any claim, demand,
cause of action, debt or liability, including reasonable
attorneys' fees, to the extent that such an action arises out of
the gross negligence or willful misconduct of Consultant.

(c)  Notice.

In claiming any indemnification hereunder, the indemnified party
shall promptly provide the indemnifying party with written notice
of any claim, which the indemnified party believes falls within
the scope of the foregoing paragraphs. The indemnified party may,
at its expense, assist in the defense if it so chooses, provided
that the indemnifying party shall control such defense, and all
negotiations relative to the settlement of any such claim. Any
settlement intended to bind the indemnified party shall not be
final without the indemnified party's written consent, which
shall not be unreasonably withheld.

6.  Limitation of Liability.

Consultant shall have no liability with respect to Consultant's
obligations under this Agreement or otherwise for consequential,
exemplary, special, incidental, or punitive damages even if
Consultant has been advised of the possibility of such damages.
In any event, the liability of Consultant to Client for any
reason and upon any cause of action, regardless of the form in
which the legal or equitable action may be brought, including,
without limitation, any action in tort or contract, shall not
exceed ten percent (10%) of the fee paid by Client to Consultant
for the specific service provided that is in question.

7.  Termination and Renewal.

(a)  Term.

This Agreement shall become effective on the date appearing next
to the signatures below and terminate one (1) year thereafter.
Unless otherwise agreed upon in writing by Consultant and Client,
this Agreement shall not automatically be renewed beyond its
Term.

(b)  Termination.

Either party may terminate this Agreement on thirty (30) calendar
days written notice, or if prior to such action, the other party
materially breaches any of its representations, warranties or
obligations under this Agreement. Except as may be otherwise
provided in this Agreement, such breach by either party will
result in the other party being responsible to reimburse the non-
defaulting party for all costs incurred directly as a result of
the breach of this Agreement, and shall be subject to such
damages as may be allowed by law including all attorneys' fees
and costs of enforcing this Agreement.

(c)  Termination and Payment.

Upon any termination or expiration of this Agreement, Client
shall pay all unpaid and outstanding fees through the effective
date of termination or expiration of this Agreement. And upon
such termination, Consultant shall provide and deliver to Client
any and all outstanding services due through the effective date
of this Agreement.

8.  Miscellaneous.

(a)  Independent Contractor.

This Agreement establishes an "independent contractor"
relationship between Consultant and Client.

(b)  Rights Cumulative; Waivers.

The rights of each of the parties under this Agreement are
cumulative.  The rights of each of the parties hereunder shall
not be capable of being waived or varied other than by an express
waiver or variation in writing.  Any failure to exercise or any
delay in exercising any of such rights shall not operate as a
waiver or variation of that or any other such right.  Any
defective or partial exercise of any of such rights shall not
preclude any other or further exercise of that or any other such
right.  No act or course of conduct or negotiation on the part of
any party shall in any way preclude such party from exercising
any such right or constitute a suspension or any variation of any
such right.

(c)  Benefit; Successors Bound.

This Agreement and the terms, covenants, conditions, provisions,
obligations, undertakings, rights, and benefits hereof, shall be
binding upon, and shall inure to the benefit of, the undersigned
parties and their heirs, executors, administrators,
representatives, successors, and permitted assigns.

(d)  Entire Agreement.

This Agreement contains the entire agreement between the parties
with respect to the subject matter hereof.  There are no
promises, agreements, conditions, undertakings, understandings,
warranties, covenants or representations, oral or written,
express or implied, between them with respect to this Agreement
or the matters described in this Agreement, except as set forth
in this Agreement.  Any such negotiations, promises, or
understandings shall not be used to interpret or constitute this
Agreement.

(e)  Assignment.

Neither this Agreement nor any other benefit to accrue hereunder
shall be assigned or transferred by either party, either in whole
or in part, without the written consent of the other party, and
any purported assignment in violation hereof shall be void.

(f)  Amendment.

This Agreement may be amended only by an instrument in writing
executed by all the parties hereto.

(g)  Severability.

Each part of this Agreement is intended to be severable.  In the
event that any provision of this Agreement is found by any court
or other authority of competent jurisdiction to be illegal or
unenforceable, such provision shall be severed or modified to the
extent necessary to render it enforceable and as so severed or
modified, this Agreement shall continue in full force and effect.

(h)  Section Headings.

The Section headings in this Agreement are for reference purposes
only and shall not affect in any way the meaning or
interpretation of this Agreement.

(i)  Construction.

Unless the context otherwise requires, when used herein, the
singular shall be deemed to include the plural, the plural shall
be deemed to include each of the singular, and pronouns of one or
no gender shall be deemed to include the equivalent pronoun of
the other or no gender.

(j)  Further Assurances.

In addition to the instruments and documents to be made, executed
and delivered pursuant to this Agreement, the parties hereto
agree to make, execute and deliver or cause to be made, executed
and delivered, to the requesting party such other instruments and
to take such other actions as the requesting party may reasonably
require to carry out the terms of this Agreement and the
transactions contemplated hereby.

(k)  Notices.

Any notice which is required or desired under this Agreement
shall be given in writing and may be sent by personal delivery or
by mail (either a. United States mail, postage prepaid, or b.
Federal Express or similar generally recognized overnight
carrier), addressed as follows (subject to the right to designate
a different address by notice similarly given):

To Client:

Mr. Thomas S. Hughes
eConnect
2500 Via Cabrillo Marina, Suite 112
San Pedro, California 90731

To Consultant:

Mr. Edward James Wexler
P.O. Box 1029
Debary, Florida 32713

(l)  Governing Law.

This Agreement shall be governed by the interpreted in accordance
with the laws of the State of California without reference to its
conflicts of laws rules or principles.  Each of the parties
consents to the exclusive jurisdiction of the federal courts of
the State of California in connection with any dispute arising
under this Agreement and hereby waives, to the maximum extent
permitted by law, any objection, including any objection based on
forum non coveniens, to the bringing of any such proceeding in
such jurisdictions.

(m)  Consents.

The person signing this Agreement on behalf of each party hereby
represents and warrants that he has the necessary power, consent
and authority to execute and deliver this Agreement on behalf of
such party.

(n)  Survival of Provisions.

The representations and warranties contained in Article VIII of
this Agreement and any liability of one Constituent Corporation
to the other for any default under the provisions of Articles VII
or VIII of this Agreement, shall expire with, and be terminated
and extinguished by, the merger under this Agreement on the
Effective Date.

(o)  Execution in Counterparts.

This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original and all of which
together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed and have agreed to and accepted the terms herein on this
date, appearing next to their signatures.

eConnect

By :  /s/  Thomas S. Hughes
Thomas S. Hughes, President

Edward James Wexler

/s/  Edward James Wexler<PAGE>   1

                                                                    EXHIBIT 10.1

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                          Under 17 C.F.R. Sections 200.80(b)(4),
                                                            200.83 and 240.24b-2

                          RESEARCH AND OPTION AGREEMENT

between

BOEHRINGER INGELHEIM INTERNATIONAL GmbH
55218 Ingelheim
GERMANY

                                              (hereinafter referred to as "BII")

and

GENETRONICS, INC.
11199 Sorrento Valley Road
San Diego
California 92121-1334
USA

                                      (hereinafter referred to as "GENETRONICS")

<PAGE>   2

                                TABLE OF CONTENTS

<TABLE>
<S>  <C>                                                                      <C>
1.   DEFINITIONS...............................................................4

2.   CONDUCT OF RESEARCH.......................................................8

3.   CONSIDERATION............................................................10

4.   RESEARCH OPTION..........................................................11

5.   DEVELOPMENT AND LICENSE OPTION...........................................13

6.   OPTION FEE...............................................................14

7.   WARRANTIES AND LIABILITIES...............................................14

8.   CONFIDENTIALITY..........................................................16

9.   INVENTIONS...............................................................18

10.  PATENTS..................................................................18

11.  PUBLICATIONS.............................................................20

12.  TERM AND TERMINATION.....................................................21

13.  CONCLUDING PROVISIONS....................................................22

APPENDIX 1 RESEARCH PLAN......................................................25

APPENDIX 2 LICENSE TERMS......................................................31
</TABLE>

                                      -2-
<PAGE>   3

WITNESSETH:

WHEREAS, BII has expressed an interest in the application of in vivo
electroporation for the delivery of DNA in solution, or in particles, into human
skin or other tissue; and

WHEREAS, BII has extensive expertise in the field of gene transfer and tumor
vaccines and has developed a variety of approaches to tumor vaccination; and

WHEREAS, Genetronics has broad technology and expertise in the field of in vivo
electroporation for intradermal and transdermal delivery of genes and drugs and
has, over a period of years, expended considerable effort and resources in the
development of technology in the area of electroporation and related
technologies for drug and gene delivery, and has accumulated extensive
experience in such areas; and

WHEREAS, BII and Genetronics have entered into discussions and have agreed upon
the content of a research project which will include the use of technologies and
methodologies proprietary to either Genetronics or BII; and

WHEREAS, Genetronics is willing to perform the Research Program in collaboration
with BII; and

WHEREAS, BII is willing to provide the funding for the Research Program; and

WHEREAS, BII wishes to obtain an option right with respect to a license to
develop and commercialize electrically assisted DNA vaccine delivery and
Genetronics is willing to grant such option;

NOW, THEREFORE, and in consideration of the foregoing premises and other good
and valuable consideration, the receipt of which is hereby acknowledged, the
parties agree as follows:

                                      -3-
<PAGE>   4

1.      DEFINITIONS

1.1     "Affiliates" shall mean any company or business entity which controls,
        is controlled by, or is under common control with either Genetronics or
        BII. For this purpose "control" shall mean direct or indirect beneficial
        ownership of at least fifty per cent (50%) of the voting share capital
        in such company or other business entity.

1.2     "BII Invention" shall mean any patentable and/or non-patentable
        invention made solely by one or more BII employees, without inventive
        contribution of Genetronics employees, pursuant to the Research Program
        or in relation to the development, manufacture, marketing or sale of a
        Product-Kit.

1.3     "BII Technology" shall mean (i) all Patent Rights and Know How owned by
        or licensed to BII as of the Effective Date that are directly related to
        tumor antigens, DNA encoding tumor antigens, tumor vaccines, vaccine
        formulations, gene transfer technology and/or tumor vaccination, (ii)
        all BII Inventions and BII Research Program Know How that are not within
        Genetronics Core Technology, and (iii) all Genetronics Inventions,
        Genetronics Research Program Know How, Joint Inventions, and Joint
        Research Program Know How that are not within Genetronics Core
        Technology and are directly related to tumor antigens, DNA encoding
        tumor antigens, tumor vaccines, vaccine formulations, gene transfer
        technology, and/or tumor vaccination.

1.4     "BII Patent Rights" shall mean any and all Patent Rights in BII
        Technology owned by or licensed to BII.

1.5     "BII Product" shall mean one or more nucleic acids encoding [...***...]
        and all other material for inclusion in a Product-Kit with the exception
        of any components purchased from Genetronics or a Genetronics Affiliate.

1.6     "Biological Material" shall mean all composition of matter provided to
        Genetronics by or on behalf of BII for performance of the Research
        Program.

1.7     "Confidential Information of BII" shall mean confidential information
        disclosed by BII or an Affiliate of BII to Genetronics or an Affiliate
        of Genetronics, including but not limited to BII Technology.

                       * Confidential Treatment Requested

                                      -4-
<PAGE>   5

1.8     "Confidential Information of Genetronics" shall mean confidential
        information disclosed by Genetronics or its Affiliates to BII or its
        Affiliates, including but not limited to Genetronics CoreTechnology and
        Genetronics New Technology.

1.9     "Confidential Information" shall mean Confidential Information of
        Genetronics and/or Confidential Information of BII.

1.10    "Effective Date" shall mean the date of execution by the last party to
        sign this Agreement.

1.11    "Electrically Assisted Delivery" shall mean the delivery of matter
        across biological barriers such as cell membranes or layer(s) of the
        skin, facilitated by the effect of electrical fields or currents on such
        biological barriers and/or on the matter to be delivered.

1.12    "Equipment" shall mean the equipment defined in Appendix 1.

1.13    "Extended Research Program" shall have the meaning set forth in Clause
        4.1.

1.14    "Extended Research Program Plan" shall have the meaning set forth in
        Clause 4.4.

1.15    "Field" shall mean the field of cancer DNA vaccines, specifically
        defined to be [...***...] nucleic acids that code for tumor antigens,
        which may be combined with [...***...] or formulation thereof that
        elicits a [...***...] immune response against [...***...] or [...***...]
        cancer cells or cancerous tissue when administered to [...***...] or
        [...***...], respectively. For the sake of clarity, the Field does not
        include HIV DNA vaccines.

1.16    "Genetronics Core Technology" shall mean (i) all Patent Rights and Know
        How owned by or licensed to Genetronics as of the Effective Date that
        are directly related to the Electrically Assisted Delivery of any
        substance into or through organismal cells or tissues, and (ii) all
        Genetronics Inventions, BII Inventions, Joint Inventions, and Research
        Program Know How that are directly related to the Electrically Assisted
        Delivery of any substance into or through organismal cells or tissues.

                       * Confidential Treatment Requested

                                      -5-
<PAGE>   6

1.17    "Genetronics Invention" shall mean any patentable and/or non-patentable
        invention made solely by one or more Genetronics employees, without
        inventive contribution of BII employees, pursuant to the Research
        Program or in relation to the development, manufacture, marketing or
        sale of a Product-Kit.

1.18    "Genetronics Patent Rights" shall mean any and all Patent Rights owned
        by or licensed to Genetronics in Genetronics Core Technology and
        Genetronics New Technology.

1.19    "Genetronics NewTechnology" shall mean all Genetronics Inventions and
        Genetronics Research Program Know How that are not within Genetronics
        Core Technology or BII Technology.

1.20    "Joint Invention" shall mean any patentable and/or non-patentable
        invention made jointly by one or more BII employees together with one or
        more Genetronics employees pursuant to the Research Program or in
        relation to the development, manufacture, marketing or sale of
        Product-Kit .

1.21    "Joint Patent Rights" shall mean Genetronics' and BII's joint Patent
        Rights in Joint Technology

1.22    "Joint Technology" shall mean all Joint Inventions and all Joint
        Research Program Know How that is not within BII Technology or
        Genetronics Core Technology.

1.23    "Know How" shall mean information which is not known to the public
        including information comprising or relating to inventions, including
        patent applications in preparation, concepts, discoveries, data,
        designs, formulae, ideas, experience; information comprising or relating
        to material, methods, models, assays, research plans, procedures,
        designs for experiments and tests and results of experimentation and
        testing including results of research or development together with
        processes including manufacturing processes, specifications, techniques,
        chemical, pharmacological, toxicological, clinical, analytical and
        quality control data, trial data, case report forms, data analyses,
        reports or summaries and correspondence no matter whether contained in
        written documents, tapes, discs, diskettes, CDROM and any other media on
        which Know How can be permanently stored. The fact that an item is known
        to the public shall not be taken to exclude the possibility that a
        compilation including the item, and/or a development related to the
        items, is (or

                                      -6-
<PAGE>   7

        remains) not known to the public.

1.24    "License Terms" shall mean the licensing terms referred to in Clause 5
        below and attached hereto as Appendix 2.

1.25    "Non-Exclusive License to Genetronics Core Technology" shall mean a
        non-exclusive, royalty-bearing license to Genetronics Core Technology in
        the Territory necessary to develop, make, use, sell, offer to sell, and
        import Product-Kits for use in the Field and as referred to in Appendix
        2 hereto attached.

1.26    "Net Sales" shall mean [...***...].

1.27    "Patent Rights " shall mean rights in all Know-How, patent applications
        and patents, design patents, improvement patents and models and
        certificates of addition and all foreign counterparts of them, including
        any provisional applications, divisional applications and patents,
        refilings, renewals, continuations, continuations-in-part, patents of
        addition, extensions, reissues, substitutions, confirmations,
        registrations, revalidation and additions of or to any of them, as well
        as any supplementary protection certificates, and equivalent protection
        rights in respect of any of them.

1.28    "Product-Kit" shall mean the finished product containing a BII Product
        combined with components purchased from Genetronics or Genetronics
        Affiliates for the Electrically Assisted Delivery of a BII Product. Each
        Specified Product-Kit is a subset of Product-Kit and shall be considered
        a Product-Kit for all purposes and definitions of this Agreement, except
        as expressly stated otherwise.

1.29    "Research Program Know How" shall mean Know How that is created,
        generated or developed by or on behalf of BII ("BII Research Program
        Know How"), by or on behalf of Genetronics ("Genetronics Research
        Program Know How"), or jointly ("Joint Research Program Know How")
        pursuant to the Research Program or in relation to development,
        manufacture, marketing or sale of the Product-Kit.

1.30    "Research Program" shall mean the research project entitled: "Delivery
        of certain cancer DNA vaccines by in vivo electroporation or related
        technologies" as set forth in detail in the Research Plan, which will be
        conducted by Genetronics and BII in collaboration in the Field pursuant
        to Clauses 2 and 7 of this Agreement. The Extended Research Program is a
        subset of Research Program and shall be

                       * Confidential Treatment Requested

                                      -7-
<PAGE>   8

        considered a Research Program for all purposes and definitions of this
        Agreement, except as expressly stated otherwise.

1.31    "Research Plan" shall mean the project as described in the protocol and
        the respective timelines attached hereto as Appendix 1, as amended from
        time to time in writing with the mutual written consent of both parties.

1.32    "Territory" shall mean the world.

2.      CONDUCT OF RESEARCH

2.1     The Research Program is a program for collaborative research under which
        Genetronics shall, among other things, develop electrodes for the in
        vivo electroporation of DNA encoding one or more tumor antigens to
        elicit an antitumor immune response. Genetronics and BII will carry out
        the research activities allocated to them in accordance with the
        Research Plan set forth in Appendix 1 of this Agreement. The Research
        Program shall begin on the Effective Date and shall terminate 18 months
        thereafter, except as it may be extended pursuant to Clause 4 of this
        Agreement.

2.2     Genetronics shall be responsible to perform all activities necessary to
        conduct its part of the Research Program as described in the Research
        Plan in Appendix 1 and within the timelines set forth therein at its own
        cost and expense.

2.3     BII will use its experience and the BII Technology to discover, develop,
        and/or acquire potential BII Products for use in the Research Program at
        its own cost and expense.

2.4     The parties shall meet at least every six (6) months to discuss the
        progress of the Research Program. The meetings shall be held at
        locations that are agreed upon by the parties, and all expenses
        associated with attending the meetings shall be borne by BII.

        Each party shall provide the other party with all Know How in its
        possession as of the Effective Date and during the term of the Research
        Program, which it has the right to disclose, to the extent necessary for
        the successful conduct of the Research Program.

                                      -8-
<PAGE>   9

2.5     Genetronics shall furnish BII with interim reports of observations and
        results of the different phases of the Research Program every 3rd month
        (quarterly) after commencement of the Research Program.

2.5     Genetronics hereby nominates [...***...] as the project manager at
        Genetronics, and BII hereby nominates [...***...] as the project manager
        at BII, who shall be jointly responsible for coordinating all work to be
        conducted under the Research Program.

        Genetronics shall use its best reasonable efforts to ensure that there
        are no changes in the person of the project manager. If a change,
        nevertheless, occurs, Genetronics will promptly submit the name and
        qualification of any planned replacement for the project manager,
        whereupon BII shall, at its sole discretion, approve or reject any such
        replacement within a reasonable time.

        The parties shall each nominate a deputy for each of these individuals,
        who shall be entitled to represent such individuals in the event of
        absence of the same.

2.6     Genetronics shall further provide BII with a complete and detailed draft
        final report of observations and results of the Research Program to date
        no later than 30 (thirty) days before completion of the Research Program
        for BII's review and approval. Upon written request of BII provided no
        later than 10 (ten) days after receipt of the draft final report,
        Genetronics shall make any reasonable modifications in such draft final
        report after receipt of BII's written request, such that a final report
        shall be complete and provided to BII no later than 18 months after
        beginning the Research Program. If BII does not timely request that
        modifications be made to the draft final report, as set forth herein,
        then the draft final report provided by Genetronics shall become the
        final report.

2.7     Genetronics agrees to provide Equipment to BII promptly after initiation
        of the Research Program. BII agrees it shall use the Equipment only
        within the Field and only pursuant to the Research Program, and shall
        abide by the following terms and conditions:

        a.     BII shall not analyze, have analyzed, structurally modify, or
               have modified the Equipment in any way.

                       * Confidential Treatment Requested

                                      -9-
<PAGE>   10

        b.     Genetronics shall retain all right, title, and interest in the
               Equipment provided to BII under this Agreement.

        c.     Under no circumstances is the Equipment to be used on humans.

        d.     BII shall not transfer the Equipment to a third party
               non-Affiliate without the prior written permission of
               Genetronics. BII shall have the right to transfer the Equipment
               to an Affiliate pursuant to the Research Program, provided
               however, BII shall inform Genetronics regularly on such
               transfers.

               The provisions of this Clause 2.7 shall apply accordingly for use
               of the Biological Material to be supplied by BII to Genetronics.

2.8     Genetronics hereby grants BII a limited license to use Genetronics Core
        Technology and Genetronics New Technology to the extent necessary for
        BII to perform the Research Program as set forth in the Research Plan
        for the term of this Agreement. BII hereby grants Genetronics a limited
        license to use BII Technology to the extent necessary for Genetronics to
        perform the Research Program as set forth in the Research Plan for the
        term of this Agreement. Each party shall have the right to sublicense
        such right to its Affiliate(s) solely for fulfilment of its obligations
        under this Agreement. No other license is granted by one party to the
        other pursuant to this Agreement.

2.9     Genetronics hereby assigns to BII its rights in any Genetronics
        Invention, Research Program Know How, and Joint Invention that is not
        within Genetronics Core Technology and that relates to tumor antigens,
        DNA encoding tumor antigens, tumor vaccines, vaccine formulations, gene
        transfer technology, and/or tumor vaccination. BII hereby assigns to
        Genetronics its rights in any BII Invention, Research Program Know How,
        and Joint Invention that is directly related to the Electrically
        Assisted Delivery of any substance into or through organismal cells or
        tissues.

3.      CONSIDERATION

3.1     In consideration of the work to be conducted by Genetronics under the
        Research Program, BII shall place at the disposal of Genetronics the
        total sum of [...***...] which shall be payable according to the
        provisions of this Clause 3. Said

                       * Confidential Treatment Requested

                                      -10-
<PAGE>   11

        total sum shall be exclusive of value added tax which shall be added
        thereon by BII, if applicable.

3.2     The sum referred to in Clause 3.1 above shall become duly payable in
        accordance with the following schedule:

        (i)    [...***...] upon execution of this Agreement;

        (ii)   [...***...]

        (iii)  [...***...]

        (iv)   [...***...]

        (v)    [...***...]

        (vi)   [...***...] upon receipt of the final report of the Research
               Program.

3.3     BII undertakes to make all payments due hereunder within 30 (thirty)
        days of receipt of an invoice by Genetronics, detailing value added tax
        separately as needed, to a bank account designated by Genetronics.

3.4     The sum referred to in Clause 3.1 above is inclusive of all costs and
        expenses of Genetronics (internal and pass-through costs) incurred in
        connection with the Research Program, except as explicitly provided
        otherwise in this Agreement. Genetronics shall assign [...***...] to the
        Research Program, [...***...] shall be a Ph.D. level scientist and
        [...***...] shall be at the level of at least a research technician, and
        [...***...] shall be qualified to perform the Research Program as set
        forth in Appendix 1.

4.      RESEARCH OPTION

4.1     BII has the right to request one 18 (eighteen) month extension of the
        Research Program if BII, in its sole discretion, decides that further
        basic research should be conducted. Such right shall be exercisable by
        notice in writing to Genetronics within 3 (three) months after BII
        receives the final report of the Research Program. If BII exercises its
        option during such period, this Agreement shall be automatically

                       * Confidential Treatment Requested

                                      -11-
<PAGE>   12

        extended for one 18 (eighteen) month period, beginning on the date of
        such written notice, under the same terms and conditions set forth
        herein, but for the right to any additional extensions ("Extended
        Research Program"). For the Extended Research Program, a consideration
        of [...***...] of the total amount set forth in Clause 3.1 is foreseen.
        In the event the Extended Research Program requires increased or
        decreased staffing and costs compared to the original Research Program,
        the parties shall jointly agree upon amounts greater or lower than
        [...***...] to fund the Program as the case may be. The consideration
        shall be paid in [...***...] equal installments. The first such payment
        shall be due by the beginning of the Extended Research Program, the next
        [...***...] installments at the beginning of the then following
        [...***...] calendar quarters and the last installment upon receipt of
        the final report of the Extended Research Program.

4.2     BII shall reimburse Genetronics for staff allocated to future questions
        resulting out of the Research Program in an amount of [...***...] per
        month for the period between the end of the original Research Program
        and (i) notification of BII's decision to enter the Extended Research
        Program or (ii) notification that BII has decided not to enter the
        Extended Research Program or (iii) expiry of the option period pursuant
        to Clause 4.1 without any notice, whichever of (i) - (iii) occurs first.
        Each payment shall be made by BII on a monthly basis until the first to
        occur of (i) - (iii).

4.3     The parties may mutually decide to extend the Research Program for a
        period shorter than 18 (eighteen) months, and under terms and conditions
        they may agree upon, but neither party has an obligation to do so.

4.4     Within a reasonable period of time following notification of BII's
        exercise of its option to enter the Extended Research Program, the
        parties shall prepare and mutually agree upon a detailed "Extended
        Research Program Plan". Such Extended Research Program Plan shall
        describe in detail the work to be carried out by Genetronics and BII
        during the Extended Research Program.

4.5     In the event the Agreement is not extended pursuant to Clause 4.1 or
        4.3, it shall be deemed terminated as of the end of 3 (three) months
        after receipt of the final report by BII. Other than rights and
        obligations under the option set forth in Clause 5 below, and
        obligations that extend after termination, as set forth in Clause 12.1,
        the parties shall have no further obligations to each other.

                       * Confidential Treatment Requested

                                      -12-
<PAGE>   13

5.      DEVELOPMENT AND LICENSE OPTION

5.1     During the performance of the Research Program or, if extended, the
        Extended Research Program or a program extension under Clause 4.3, and
        for a three month period after such has been conducted, BII may, in its
        sole discretion, decide to enter into a development and license
        agreement with Genetronics, the major terms of which are set forth in
        the License Terms attached hereto as Appendix 2. Such option right shall
        be exercisable by notifying Genetronics at the latest 3 (three) months
        after receipt of the final report of the Research Program, receipt of
        the final report of the Extended Research Program, or completion of the
        Clause 4.3 research extension, as the case may be. In the event BII
        exercises the option granted under this Clause 5.1 during the term of
        the Research Program, the Extended Research Program, or a program
        extension under Clause 4.3, BII shall either (i) terminate the Agreement
        pursuant to the terms of Clause 12.3, or (ii) continue to make all
        payments to Genetronics as agreed to, and on the schedule, pursuant to
        Clauses 3.2, 4.1 or 4.3, as the case may be, as consideration for
        development activities to be assigned to Genetronics under the license
        and development agreement. The choice between (i) and (ii) shall be made
        solely by BII.

5.2     Genetronics and BII shall negotiate all terms of a development and
        license agreement that are not already agreed upon in the License Terms
        during the initial Research Program, such that a finally negotiated and
        drafted development and license agreement shall be in a form for
        execution at completion of the Research Program. Upon exercise of the
        option pursuant to Clause 5.1, and in the event the development and
        license agreement is not yet in finally negotiated and drafted form, the
        parties shall enter into good faith, timely, negotiations on all
        remaining terms of such development and license agreement not already
        agreed upon in the License Terms, including but not limited to
        provisions concerning diligent development, warranties, liabilities,
        termination, and effect of termination appropriate for such kind of
        agreement.

5.3     If the parties fail to agree upon the remaining terms, and (i) such
        failure is a result of reasonable differences in opinion between the
        parties with respect to a substantive term of the agreement, and (ii)
        such failure is not a result of Genetronics desiring to enter into a
        license and development agreement with a third party instead of BII, and
        (iii) a final development and license agreement has not been concluded
        within four (4) months after the option pursuant to Clause 5.1 has been
        exercised, then BII's option

                                      -13-
<PAGE>   14

        right shall be deemed to have expired. Neither Party shall have any
        further right to negotiate with the other party. In the event of such
        failed negotiations, and upon request of BII at the end of the four (4)
        month negotiation period, Genetronics shall warrant and represent to BII
        in writing that its failure to agree with BII as to all terms of the
        development and license agreement is a result of a sincere difference of
        opinion and is not a result of Genetronics desiring to enter into a
        license and development agreement with a third party instead of BII.

6.      OPTION FEE

6.1     If BII enters into an extension under Clause 4.1 or 4.3, or exercises
        its option to enter into a development and license agreement granted
        under Clause 5.1, a one time option fee of [...***...] will be paid to
        Genetronics by BII within 30 (thirty) days notifying Genetronics of the
        first to occur of an extension or exercise of the development and
        license right, and receipt of a respective invoice.

7.      WARRANTIES AND LIABILITIES

7.1     Genetronics represents and warrants that:

        (i)    it will use its best endeavours to carry out the Research Program
               as set forth in the Research Plan and within the times agreed
               upon in Appendix 1, with all reasonable care and skill in
               accordance with all applicable laws, professional standards and
               in accordance with all provisions of this Agreement, with both
               parties acknowledging that it may not be possible to complete all
               research outlined in Appendix 1 within the eighteen month term
               due to reasons beyond the parties' control;

        (ii)   it shall devote the efforts of suitably qualified and trained
               employees capable of carrying out the Research Program to a
               professional standard and shall provide all necessary facilities
               therefor;

        (iii)  all reports, documentation and information to be provided to BII
               hereunder shall be compiled in accordance with best scientific
               practice and delivered in a form agreed upon in advance with BII;

                       * Confidential Treatment Requested

                                      -14-
<PAGE>   15

        (iv)   the Genetronics Core Technology and Genetronics New Technology is
               owned by Genetronics or an Affiliate and it will use its best
               reasonable endeavours to see that such will continue to be the
               case during the term of this Agreement;

        (v)    the Genetronics Core Technology and Genetronics New Technology is
               free of any mortgage, charge or other encumbrance and it will use
               its best reasonable endeavours to see that such will continue to
               be the case during the term of this Agreement.

7.2     Each party represents and warrants that:

         (i) it has legal power, authority and right to enter into this
         Agreement and to properly perform its respective obligations in this
         Agreement; and

         (ii) it is not as of the Effective Date a party to any agreement,
         arrangement or understanding with any third party which in any way
         prevents it from fulfilling any of its obligations under the terms of
         this Agreement.

7.3      BII hereby indemnifies and holds harmless Genetronics from and against
         all third party claims, including without limitation, any claims with
         respect to death or injury to a person or damage to property, and all
         damages, losses, costs and expenses, including reasonable attorney's
         fees, which Genetronics may incur arising out of or resulting from (i)
         the conduct of the Research Plan solely performed by BII, its
         Affiliates or sublicensees, and/or (ii) the negligence, recklessness or
         willful misconduct of BII, its Affiliates or sublicensees or each of
         their officers, employees or agents.

7.4      Genetronics hereby indemnifies and holds harmless BII and its
         Affiliates from and against all third party claims, including without
         limitation, any claims with respect to death or injury a person or
         damage to property, and all damages, losses, costs and expenses,
         including reasonable attorney's fees, which BII or its Affiliates may
         incur arising out of or resulting from (i) conduct of the Research Plan
         solely performed by Genetronics and/or (ii) the negligence,
         recklessness or willful misconduct of Genetronics or its officers,
         employees or agents.

7.5      The party seeking indemnification under Clause 7.3 or 7.4 (the
         "Indemnified Party") shall (i) give the other party (the "Indemnifying
         Party") notice of the relevant claim,

                                      -15-
<PAGE>   16

        (ii) cooperate with the Indemnifying Party, at the Indemnifying Party's
         expense, in the defence of such claim and (iii) give the Indemnifying
         Party the right to control the defence and settlement of such claim,
         except that the Indemnifying Party shall not enter into any settlement
         that affects the Indemnified Party's rights or interest without the
         Indemnified Party's prior written approval. The Indemnified Party shall
         have no authority to settle any claim on behalf of the Indemnifying
         Party. A party's obligation to indemnify the other pursuant to Clause
         7.3 or 7.4 shall be waived with respect to a certain claim in the event
         a party seeking to be indemnified does not provide notice of the
         relevant claim in sufficient time for the other party to respond or
         defend against the claim.

8.      CONFIDENTIALITY

8.1     In relation to Confidential Information disclosed by one party to the
        other and subject to Clauses 8.2 and 8.3 below, each party agrees:

        (i)    not to publish or provide or make available any of the other
               party's Confidential Information in any form to any third party;
               and

        (ii)   not to use or reproduce any of the other party's Confidential
               Information except for use reasonably necessary for its
               performance of this Agreement.

8.2     Each party may provide or make available the Confidential Information
        disclosed by the other:

        (i)    to those of its employees who have a need to know consistent with
               the receiving party's authorized use of that Confidential
               Information; and

        (ii)   in the case of BII, to official organizations responsible for
               granting marketing authorizations; and

        (iii)  in the case of Genetronics, to [...***...]., (i) only as far as
               Genetronics Core Technology is concerned; no information on BII
               Technology and no confidential information on BII's or BII's
               Affiliates' trade secrets, business affairs or finances are to be
               disclosed to [...***...] and (ii) only to the extent necessary
               for Genetronics to fulfill its obligation to provide [...***...]
               with

                       * Confidential Treatment Requested

                                      -16-
<PAGE>   17

               [...***...] with respect to any development and license agreement
               pertaining to [...***...].

        (iv)   to Affiliates of the parties in order to reasonably perform this
               Agreement, in which event recipients of the Confidential
               Information shall be bound by written obligations of
               confidentiality no less onerous than those contained in this
               Clause 8; and

        (v)    to comply with the disclosure obligations of the patent laws of
               any jurisdiction in connection with any patent application
               relating to BII Technology, Genetronics Core Technology,
               Genetronics New Technology, or Joint Technology or any component
               thereof.

8.3     The obligations of confidentiality and non-use in Clause 8.1 above shall
        not apply to any part of the Confidential Information which:

        (i)    is in or comes into the public domain in any way without breach
               of this Agreement by the receiving party; or

        (ii)   the receiving party can show was in its possession or known to it
               by being in its use or being recorded in its files or computers
               or other recording media prior to receipt from the disclosing
               party and was not previously acquired by the receiving party from
               the disclosing party; or

        (iii)  the receiving party obtains or has available from a source other
               than the disclosing party without breach by the receiving party
               or such source of any obligation of confidentiality or non-use
               towards the disclosing party; or

        (iv)   is disclosed by the receiving party (a) with the prior written
               approval of the disclosing party or (b) without such approval,
               after a period that is the longer of 20 (twenty) years from the
               date of this Agreement, 10 (ten) years from the date of
               termination of this Agreement, or if executed, 10 (ten) years
               from the date of termination of a subsequent business agreement
               between the parties that is relevant to this Agreement .

8.4     Notwithstanding the foregoing, the receiving party shall be entitled to
        make any disclosure required by any law or by any governmental authority
        of the other party's

                       * Confidential Treatment Requested

                                      -17-
<PAGE>   18

        Confidential Information provided that it gives the other party not less
        than 5 (five) working days notice of such disclosure.

8.5     Each party reserves all rights in its Confidential Information and no
        rights or obligations other than those expressly recited herein are
        granted or to be implied from this Agreement. In particular, other than
        as expressly provided in this Agreement, no license is granted by this
        Agreement directly or indirectly under any patent, invention, discovery,
        copyright or other intellectual property right now or in the future
        held, made, obtained or licensable by either party. Nothing in this
        Agreement or its operation shall preclude or in any way impair or
        restrict either party from continuing to engage in its business
        otherwise than in breach of the terms of this Agreement.

8.6     The parties agree not to disclose the terms of this Agreement to third
        parties, other than Affiliates, and neither shall make any announcement
        in relation to or otherwise publicize its contents without the prior
        written approval of the other, except as necessary under government
        rules, regulations and laws. BII agrees that Genetronics shall have the
        right to disclose this Agreement in a press release approved by BII in
        advance, which approval shall not be unreasonably withheld.

9.      INVENTIONS

9.1     By virtue of the Agreement, Genetronics shall not acquire any right to
        BII Technology or future BII gene transfer systems, other than as set
        forth in Clause 2.8.

9.2     By virtue of the Agreement, BII shall not acquire any right to
        Genetronics Core Technology or Genetronics New Technology other than as
        set forth in Clause 2.8.

10.     PATENTS

10.1    BII shall have full responsibility for, and shall bear all expenses for,
        the filing, prosecution, maintenance or other protection of BII Patent
        Rights.

10.2    Genetronics shall have full responsibility for, and shall bear all
        expenses for, the filing, prosecution, maintenance or other protection
        of Genetronics Patent Rights.

                                      -18-
<PAGE>   19

10.3    Joint Technology shall be jointly owned by both partners. The parties
        will discuss and agree which party shall have responsibility for the
        filing, prosecution and maintenance of the Joint Patent Rights on Joint
        Inventions worldwide and on the cost sharing related thereto.

10.4    Each party agrees to assist the other party in every proper way,
        including the execution of all proper documents requested by the filing
        party. If a party decides not to file, prosecute or maintain a Patent
        Right on its own Invention, or on a Joint Invention, in any country, it
        shall give the other party reasonable notice to that effect; upon
        receipt of such notice, the other party may, at its expense, file,
        prosecute or maintain such Patent Right unless the first party has
        determined to protect such invention as an intellectual property right
        other than a patent.

10.5    Each party shall promptly inform the other party of any BII,
        Genetronics, or Joint Invention of which it becomes aware during the
        term of this Agreement.

10.6    At least fourteen (14) days prior to filing of any patent application
        for an Invention within the scope of this Agreement, the party
        responsible for the filing will provide the other party with an English
        language summary of the patent application for the non-filing party's
        review and comment. The filing party will also provide the non-filing
        party with a full copy of each such patent application actually filed in
        the language in which it was originally filed.

10.7    If either party becomes aware that a Genetronics Patent Right or a Joint
        Patent Right is infringed by a third party in any country, that party
        shall promptly notify the other party in writing. Genetronics shall have
        the primary right, but not the obligation, to bring and prosecute at its
        own expense an action concerning such infringement. If Genetronics does
        not commence such an action within [...***...] of learning of such
        infringement, BII shall have the right but not the obligation to bring
        and prosecute at its own expense an action concerning such infringement.
        The parties shall cooperate with each other in connection with any
        action brought under this Clause 10.7. Any monetary award granted to the
        prosecuting party hereunder shall be applied first to the costs and
        expenses of the party prosecuting the action, then to the costs and
        expenses of the other party. The party bringing the suit shall be
        entitled to any monetary awards in excess.

                                      -19-
<PAGE>   20

10.8    The parties shall assist each other to secure the proper documentation
        to assign rights consistent with the grants set forth in Clause 2.9.

10.9    The inventorship of a BII Invention, Genetronics Invention and Joint
        Invention will be determined pursuant to relevant appropriate laws of
        the jurisdiction in which a patent application directed to the Invention
        is to be filed. To the extent it is necessary to determine inventorship
        or ownership of intellectual property that is not the subject of a
        patent application, Genetronics and BII will make a determination based
        on the facts, fairness, and, if applicable, relevant laws.

11.     PUBLICATIONS

        During the term of this Agreement, Genetronics and BII each acknowledges
        the other party's interest in publishing certain of its results to
        obtain recognition within the scientific community and to advance the
        state of scientific knowledge. Each party also recognizes the mutual
        interest in obtaining valid intellectual property protection and
        maintaining as confidential any information related to non-patentable
        technology which would have commercial value when undisclosed.
        Consequently, either party, its employees or consultants wanting to make
        a publication (including any oral disclosure) relating to work performed
        by such party as part of the Research Program (the "Publishing Party")
        shall transmit to the other party (the "Reviewing Party") a copy of the
        proposed written publication at least ninety (90) days prior to
        submission for publication, or an outline of such oral disclosure at
        least sixty (60) days prior to presentation. The Reviewing party shall
        have the right (a) to propose modification to the publication for patent
        or other reasons and (b) to request a delay in publication in order to
        protect patentable information.

        If the Reviewing Party requests such a delay, the Publishing Party shall
        delay submission or presentation of the publication for a period not
        longer than ninety (90) days to enable patent applications protecting
        each party's rights in such information to be filed in accordance with
        Article 10. If the Reviewing Party reasonably claims that such
        information, whether or not patentable, may have significant commercial
        value and can be maintained as a trade secret, the Publishing Party
        shall publish or disclose only such information which would not
        adversely affect such commercial value. Upon the expiration of ninety
        (90) days or sixty (60) days from transmission to the Reviewing Party,
        as applicable, the Publishing Party shall be free to proceed with

                                      -20-
<PAGE>   21

        the written publication or the presentation, respectively, unless the
        Reviewing Party has requested the trade secret protection described
        above.

12.     TERM AND TERMINATION

12.1    This Agreement shall commence on the Effective Date and shall terminate
        upon the first to occur of (i) completion of the Research Program with a
        duration of 18 (eighteen months and expiration or termination of the
        option in Clause 4.1 or 4.3 without exercise, (ii) completion of the
        Extended Research Program with a duration of 18 (eighteen) months and
        expiration, termination, or exercise of the option in Clause 5.1, if BII
        has exercised its option pursuant to Clause 4.1, or (iii) completion of
        an extended research program the parties may agree upon pursuant to
        Clause 4.3 and expiration, termination, or exercise of the option in
        Clause 5.1. The following Clauses shall survive termination of this
        Agreement: 2.6 (final report); 5.3 (in event of no agreement on
        license); 6.1 (option fee); 7.3, 7.4 and 7.5 (indemnification); 8
        (confidentiality); 9 (invention); 10 (patents); 11 (publications); 12.1
        (survival); 12.3 (early termination), 12.4 (effects of termination);
        12.5 (return of equipment); 13.1 (Affiliates); 13.6 (choice of law);
        Appendix 2 (partial license terms).

12.2    This Agreement may be terminated with immediate effect by written notice
        by either party, if the other party breaches this Agreement in any
        material manner and shall have failed to remedy such default within 30
        (thirty) days after written notice thereof by the terminating party.

12.3    BII shall be entitled to terminate this Agreement forthwith at any time
        upon written notice to Genetronics thereof. In such an event, BII shall
        be obligated to pay Genetronics the difference between (i) the amount
        set forth in Clause 3.1 or agreed upon pursuant to Clause 4.1 or 4.3, as
        the case may be and (ii) the amount that will have been paid to
        Genetronics as of the date of early termination.

        However, if BII has terminated this Agreement in accordance with the
        provisions of Clause 12.2 above, BII shall only be obliged to pay to
        Genetronics the amounts due on the date of termination pursuant to
        Clause 3 or 4, as the case may be.

12.4    Upon termination of this Agreement for any reason, any license or option
        right granted from one party to the other, either expressly or
        impliedly, pursuant to this Agreement, including but not limited to the
        license grants under Clause 2.8, shall revert to the

                                      -21-
<PAGE>   22

        granting party, with the exception of any such right granted in a
        subsequent license or other agreement between the parties. BII shall
        retain all ownership rights in BII Technology, regardless of
        inventorship. Genetronics shall retain all ownership rights in
        Genetronics Core Technology and Genetronics New Technology, regardless
        of inventorship. Absent an express license subsequently granted by one
        party to the other, neither party shall have the right to practice
        within the other's Technology.

12.5    Upon termination of the Agreement, each party shall promptly return the
        Equipment or the Biological Material, as the case may be, or dispose of
        any unused portions as the other party may direct in writing.

13.     CONCLUDING PROVISIONS

13.1    Neither party shall be entitled to assign or otherwise transfer its
        rights and obligations under this Agreement in whole or in part to any
        third party without the prior written consent of the other party except
        to its Affiliates. BII shall have the right to exercise any of its
        rights or perform any of its obligations hereunder through any of its
        Affiliates and to the extent it does so it hereby guarantees such
        performance. BII shall be responsible for all payments due to
        Genetronics under this Agreement and BII shall ensure that any Affiliate
        performs all its obligations under the sub-license granted to it by BII.
        BII indemnifies Genetronics against all loss, damage, cost or expense
        which Genetronics may incur as a result of failure by such Affiliate or
        BII to perform obligations under any such sub-license equivalent to any
        obligation of BII hereunder. If also Genetronics wishes to exercise its
        rights or perform its obligations through an Affiliate the provisions of
        this Clause 13.1 shall apply accordingly to Genetronics.

        With respect to any reference to BII or Genetronics in the definition of
        a party's sole or Joint Invention, Technology, Patent Rights, Product,
        Confidential Information, Core Technology, Know How, and Research
        Program Know How, it is the parties' intent that "BII" shall mean "BII
        or its Affiliates" and "Genetronics" shall mean "Genetronics or its
        Affiliates".

13.2    This Agreement sets forth the entire agreement between the parties and
        supersedes all previous agreements, written or oral regarding the
        subject matter hereof. This Agreement may be amended only by an
        instrument in writing duly executed on behalf of the parties.

                                      -22-
<PAGE>   23

13.3    Neither party shall be liable for delay or failure to perform hereunder
        due to any contingency beyond its control, including, but not limited to
        acts of God, fires, floods, wars, civil wars, sabotage, strikes,
        governmental laws, ordinances, rules or regulations or failure of third
        party delivery, provided, such party promptly gives to the other party
        hereto written notice claiming force majeure and uses its best efforts
        to eliminate the effect of such force majeure, insofar as is possible
        and with all reasonable dispatch. If the period of delay of failure
        should extend for more than 3 (three) months then either party shall
        have the right to terminate this Agreement forthwith upon written notice
        at any time after expiration of said 3 (three) months period.

13.4    Any waiver shall be made in writing for it to be effective and unless
        expressly stated shall not be a continuing waiver not shall it prevent
        the waiving party from acting upon that or any subsequent breach or from
        enforcing any term or condition of this Agreement.

13.5    The invalidity of any provision of this Agreement shall not affect the
        validity of any other provision hereof. The parties undertake to replace
        any invalid provision in the Agreement with another provision which
        reflects legally the originally intended commercial objectives of the
        parties as closely as possible.

13.6    This Agreement shall be governed exclusively by [...***...] law. In the
        event of any controversy or claim arising out of or relating to any
        provision of this Agreement, the parties shall first try to settle those
        conflicts amicably between themselves. All disputes arising in
        connection with this Agreement, which cannot be settled amicably, shall
        be litigated in the [...***...], provided any lawsuit shall be filed in
        the Federal Courts and the parties hereby consent to waive any
        Constitutional, Statutory or Common Law of trial by Jury.

13.7    In the performance of this Agreement each party shall be an independent
        contractor, and therefore, no party shall be entitled to any benefits
        applicable to any employee of the other party. No party is authorized to
        act as an agent for the other party for any purpose, and no party shall
        enter into any contract, warranty or representation as to any matter on
        behalf of the other party.

                       * Confidential Treatment Requested

                                      -23-
<PAGE>   24

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
in duplicate by their duly authorized representatives.

Ingelheim, Germany                                     San Diego, California

BOEHRINGER INGELHEIM                                   GENETRONICS, INC.
INTERNATIONAL GMBH

ppa.

/s/ Prof. Dr. Bernd Wetzel  Dr. Christian Hauke        /s/ Martin Nash 10/27/99
------------------------------------------------       -------------------------
                                 11/02/99

                                      -24-
<PAGE>   25

APPENDIX 1
RESEARCH PLAN

BI AUSTRIA- GENETRONICS DNA VACCINE DELIVERY PROJECT

GOAL:

The goal of this project is to determine parameters of DNA delivery by
electroporation which will yield an optimal immune response against tumor cells.

BACKGROUND/ASSUMPTIONS:

Three important factors of DNA vaccination include the design of the DNA
construct, the choice of the target tissue and the mode of DNA delivery. The
immune response will greatly depend on each one of these factors.

This project outline will focus on the [...***...] as the target tissue and
electrical pulses as the means of DNA delivery. In addition, [...***...] will be
investigated.

By designing appropriate conditions, we expect that DNA delivery into the
[...***...] by electroporation will allow, at least to some extent, us to
control DNA delivery into a certain [...***...]. This will determine the types
of cells which will receive the DNA vaccine. We also expect to be able to
control, within limits, the percentage of cells which will be transfected. These
parameters will indirectly influence the level and time course of antigen
expression, secretion and interstitial or systemic distribution. It is also
conceivable that a second series of electroporation pulses to antigen-producing
cells will substantially influence the immune response by facilitating antigen
dissemination from these cells.

Presently, the two main methods for DNA delivery are (1) direct needle injection
of a DNA solution into skin or muscle and (2) shooting DNA-coated particles into
the skin with a "gene gun." Direct needle injection into the skin or muscle is
effective to some extent in eliciting immune responses in various mammals,
including humans. However, large quantities of DNA are required and it remains
to be seen whether this approach will meet safety and economic requirements for
routine use.

Administering DNA precipitated on the surface of microscopic gold particles via
"gene gun" technology results in direct delivery of DNA into skin cells. The
amount of DNA required in

                       * Confidential Treatment Requested

                                      -25-
<PAGE>   26

this method is relatively small but mass production of the coated particles and
a safe, consistently effective delivery gun are still formidable obstacles to
overcome.

Genetronics has demonstrated that electrical pulses can be used to deliver DNA
in solution into cells of living tissue, including [...***...]. Genetronics'
technology can also deliver particles which could be coated or loaded with DNA
into [...***...]. The proposed research aims at determining the feasibility of
inducing a therapeutically or prophylactically effective immune response by
electroporation-mediated DNA delivery into [...***...].

During this project the following questions will be addressed:

1.      What are the optimal electrode designs and pulse conditions for
        introducing DNA vaccines into tissue?

2.      How does the Genetronics delivery technology compare to other methods in
        the resulting immune response? What are the advantages for vaccine
        delivery by Genetronics' technology? (e.g., [...***...])

3.      What adjuvants and/or co-factors are suitable and appropriate for
        modulation of resulting immune responses and can they be delivered
        together with DNA?

4.      Does the Genetronics delivery of vaccines elicit immune responses in
        large animals?

                       * Confidential Treatment Requested

                                      -26-
<PAGE>   27

                              EXPERIMENTAL OUTLINE

Research phase (18 months)
The proposed program is open to modifications upon mutual written agreement.

Genetronics will provide the following equipment to BII ("Equipment"):

        (i) one (1) 830 Electroporation System;

        (ii) one (1) auto switcher and one (1) manual switcher;

        (iii) various 2 needle arrays and various 6 needle arrays;

        (iv) various flat (surface) electrodes (meander, micropatch); and

        (v) any composition of matter provided to BII by or on behalf of
Genetronics for performance of the Research Program

1.      GENE EXPRESSION PROFILE IN MOUSE [...***...]

Determine DNA delivery parameters to achieve optimal antigen expression in mouse
[...***...]

Test [...***...] DNA and two different BI formulations in mice Administration:
[...***...]

Determine gene expression profile: [...***...]

Electrode design:  Meander or other non-invasive electrode

                   Needle array

                   Novel needle array

                   Other

Pulse design:      Pulse (wave) form

                   Polarity

                   Current

                   Field strength and field homogeneity

                   Pulse length

                   Number and frequency of pulses

                   Homogeneous or heterogeneous pulses

                       * Confidential Treatment Requested

                                      -27-
<PAGE>   28

If delivery through [...***...] is ineffective, [...***...]

* Confidential Treatment Requested

                                      -28-
<PAGE>   29

2.      CHARACTERIZE IMMUNE RESPONSES AFTER IN VIVO ELECTROPORATION

Genes/Models:

        Genetronics will work on: [...***...]

        BI Austria will work on: [...***...]

2.1.    Humoral immune responses in mice

Dose response

Effect of booster immunisation

Isotype profile of specific antibodies after electroporation

Longevity of response

2.2.    Cellular immune responses

[...***...]

2.3.    Efficacy in mouse models

[...***...]

3.      STUDIES TO MODIFY THE TYPE OF IMMUNE RESPONSE

[...***...]

4.      GENE EXPRESSION PROFILE IN PIG SKIN

Short term parameter study in pigs, similar to 1., using best devices and
protocols

                       * Confidential Treatment Requested

                                      -29-
<PAGE>   30

WORK PACKAGES (OVERVIEW)

0                   6              9                        18 months

[...***...]

[...***...]

                    [...***...]

                    [...***...]

                                             [...***...]

                       * Confidential Treatment Requested

                                      -30-
<PAGE>   31

APPENDIX 2

LICENSE TERMS

1.      DEFINITIONS

        The definitions set forth in Clause 1 of the Research and Option
        Agreement and Clause 13.1 are incorporated herein by reference and shall
        control, unless the text in this Appendix clearly indicates to the
        contrary.

2.      CERTAIN RIGHTS GRANTED TO BII UPON BII'S EXERCISE OF OPTION TO NEGOTIATE
        AND ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT AND THE EXECUTION OF
        SUCH AN AGREEMENT

        (i)    Non-Exclusive License to Genetronics Core Technology.

               Genetronics shall grant BII a non-exclusive, royalty-bearing
               license in the Territory to Genetronics Core Technology necessary
               to develop, make, use, sell, offer to sell, and import
               Product-Kits for use in the Field.

        (ii)   Exclusive License to Genetronics New Technology.

               Genetronics shall grant BII an exclusive, royalty-bearing license
               in the Territory to Genetronics New Technology necessary to
               develop, make, use, sell, offer to sell, and import Product-Kits
               for use in the Field.

        (iii)  In case of early termination of the license agreement because of
               Genetronics bankruptcy or material breach of contract by
               Genetronics, BII shall have a fully paid up right to manufacture,
               or have manufactured, the disposable delivery devices (e.g.,
               electrodes) for use in the Field and Genetronics will supply to
               BII all Know How and technical assistance necessary to exercise
               such manufacturing right.

        (iv)   All rights granted to BII under a development and license
               agreement shall include the right to sublicense such rights to an
               Affiliate. BII shall remain responsible to Genetronics for any
               acts, sales, and obligations of a

                                      -31-
<PAGE>   32

               sublicensee as if they were made by BII.

        (v)    This Agreement shall expire and the licenses granted by
               Genetronics to BII shall become fully paid on a
               country-by-country basis upon the last to occur of (i) expiration
               of all valid claims on Genetronics Technology in each such
               country or (ii) ten (10) years from the first commercial sale of
               a Product-Kit in each such country.

3.      CONSIDERATION

        (i)    Milestone payments:

               [...***...]

        (ii)   Royalties for Product-Kits governed by non-exclusive licenses to
               Genetronics Core Technology:

[...***...] on Net Sales; the price paid by BII for any components purchased
from Genetronics that are incorporated into the Product-Kit shall be subtracted
from the amount of Net Sales before calculating any royalties.

The [...***...] royalty rate for each Product-Kit shall be diminished by
[...***...] for each additional delivery-related license BII obtains for that
Product-Kit and by [...***...] for the first license BII obtains for a BII
Product within that Product-Kit and by [...***...] for the second and each
additional license BII obtains for a BII Product that constitutes part of that
Product-Kit. Each such decrease in royalty rate shall be made only if BII is
obligated to pay a royalty to the respective third party licensor that is
[...***...] the rate of the decrease contemplated by this Clause 3 (ii). By way
of example, in the event BII is obligated to pay a royalty for a
delivery-related license for a BII Product that is at least [...***...] of Net
Sales, then the present [...***...] royalty shall be decreased by [...***...].
Alternatively, in the event BII is obligated to pay a royalty for a
delivery-related license for a BII Product that is less than [...***...] of Net
Sales, then the present [...***...] royalty shall not be decreased by
[...***...] in recognition of that third party license. In no case shall the
royalty rate paid to Genetronics under a non-exclusive license be

                       * Confidential Treatment Requested

                                      -32-
<PAGE>   33

               less than [...***...].

        (iii)  Transfer price of disposable delivery device (e.g., electrodes)
               for a Product-Kit:

               The purchase price BII shall pay Genetronics for the single use
               disposable delivery device which is presently envisioned to be a
               component of a Product-Kit shall be the higher of (i)[...***...]
               for each single use disposable delivery device suitable for one
               vaccination (one "shot") per person, or (ii) a price [...***...]
               in excess of Genetronics manufacturing costs for such device,
               (allowing a [...***...] gross profit) but, in the event
               [...***...] of the weighted average retail price of the
               respective Product-Kit is greater than the higher of (i) or (ii),
               the purchase price for the single use disposable delivery device
               shall not exceed [...***...] of the weighted average retail price
               of the respective Product-Kit. The [...***...] upper cap may be
               revised by mutual written agreement of the parties depending on
               the progress in Product-Kit development and projected market
               conditions. BII will use, and will require its sublicensees to
               use, Genetronics disposables exclusively. In all cases
               Genetronics will use best efforts to provide BII with the
               economically best transfer price.

        (iv)   Marketing of pulse generators:

               Pulse generators shall be developed and tested in consultation
               with BII and manufactured, distributed and serviced by
               Genetronics or its Affiliates. BII shall require the exclusive
               use of Genetronics pulse generators with Genetronics'
               disposables. Pricing of pulse generators shall be the sole
               responsibility of Genetronics; however, input from BII market
               research will be welcomed in reaching a pricing decision.

        (v)    By virtue of the Agreement, Genetronics shall not acquire any
               ownership in future inventions or intellectual property rights to
               any of BII's existing or future intellectual property regarding
               gene transfer systems, except for such future inventions and/or
               intellectual property rights that fall under Genetronics Core
               Technology as defined in Clause 1.16 of the Research and Option
               Agreement.

                       * Confidential Treatment Requested

                                      -33-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]